Antenatal Diagnosis

Inherited Bleeding Disorders in Women

Volumn , Issue , 2009, Pages 99-123

  Chi, Claudia ^a   Kadir, Rezan A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Analysis of free fetal DNA (ffDNA) present in maternal blood; Antenatal diagnosis; Chorionic villus sampling prenatal diagnostic test; Inherited bleeding disorders affecting daily life and psychological wellbeing; Pre implantation genetic diagnosis (PGD); Prenatal diagnosis of hemophilia; Prenatal diagnostic techniques; Reproductive options for women with inherited bleeding disorders; sperm sorting alternative approach for women with X linked disorders; Von Willebrand disease (VWD) autosomal condition affecting males and females

Indexed keywords

EID: 84880590190     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303490.ch9     Document Type: Chapter

References (205)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-459.
2. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893-898.
3. Alfirevic Z, von Dadelszen P. Instruments for chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2003; CD000114.
4. Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database Syst Rev 2003; CD003252.
5. Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110: 687-694.
6. Firth HV, Boyd PA, Chamberlain PF, et al. Analysis of limb reduction defects in babies exposed to chorionic villus sampling. Lancet 1994; 343: 1069-1071.
7. RCOG. Amniocentesis and chorionic villus sampling. Guideline No. 8. 2005.
8. Tabor A, Philip J, Madsen M et al. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986; 1: 1287-1293.
9. The Canadian Early and Mid-trimester Amniocentesis Trial (CEMATGroup). Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. Lancet 1998; 351: 242-247.
10. Yukobowich E, Anteby EY, Cohen SM, et al. Risk of fetal loss in twin pregnancies undergoing second trimester amniocentesis (1). Obstet Gynecol 2001; 98: 231-234.
11. Fisk NM, Fordham K, Abramsky L. Elective late fetal karyotyping. Br J Obstet Gynaecol 1996; 103: 468-470.
12. Shalev J, Meizner I, Rabinerson D, et al. Elective cytogenetic amniocentesis in the third trimester for pregnancies with high risk factors. Prenat Diagn 1999; 19: 749-752.
13. Rozenberg P. [Third trimester amniocentesis for fetal karyotyping: why so late?.]. Gynecol Obstet Fertil 2002; 30: 427-430.
14. Galle PC, Meis PJ. Complications of amniocentesis: a review. J Reprod Med 1982; 27: 149-155.
15. Gordon MC, Narula K, O'Shaughnessy R, Barth WH, Jr. Complications of third-trimester amniocentesis using continuous ultrasound guidance. Obstet Gynecol 2002; 99: 255-259.
16. Stark CM, Smith RS, Lagrandeur RM, et al. Need for urgent delivery after third-trimester amniocentesis. Obstet Gynecol 2000; 95: 48-50.
17. Hodor JG, Poggi SH, Spong CY, et al. Risk of thirdtrimester amniocentesis: a case-control study. Am J Perinatol 2006; 23: 177-180.
18. Lam YH, Tang MH, Sin SY, Ghosh A. Clinical significance of amniotic-fluid-cell culture failure. Prenat Diagn 1998; 18: 343-347.
19. O'Donoghue K, Giorgi L, Pontello V, et al. Amniocentesis in the third trimester of pregnancy. Prenat Diagn 2007; 27: 1000-1004.
20. Donner C, Rypens F, Paquet V, et al. Cordocentesis for rapid karyotype: 421 consecutive cases. Fetal Diagn Ther 1995; 10: 192-199.
21. Buscaglia M, Ghisoni L, Bellotti M, et al. Percutaneous umbilical blood sampling: indication changes and procedure loss rate in a nine years' experience. Fetal Diagn Ther 1996; 11: 106-113.
22. Weiner CP, Okamura K. Diagnostic fetal blood samplingtechnique related losses. Fetal Diagn Ther 1996; 11: 169-175.
23. Tongsong T, Wanapirak C, Kunavikatikul C, et al. Cordocentesis at 16-24 weeks of gestation: experience of 1320 cases. Prenat Diagn 2000; 20: 224-228.
24. Tongsong T, Wanapirak C, Kunavikatikul C, et al. Fetal loss rate associated with cordocentesis at midgestation. Am J Obstet Gynecol 2001; 184: 719-723.
25. Liao C, Wei J, Li Q, et al. Efficacy and safety of cordocentesis for prenatal diagnosis. Int J Gynaecol Obstet 2006; 93: 13-17.
26. Orlandi F, Damiani G, Jakil C, et al. The risks of early cordocentesis (12-21 weeks): analysis of 500 procedures. Prenat Diagn 1990; 10: 425-428.
27. Antsaklis A, Daskalakis G, Papantoniou N, Michalas S. Fetal blood sampling -indication-related losses. Prenat Diagn 1998; 18: 934-940.
28. Maxwell DJ, Johnson P, Hurley P, et al. Fetal blood sampling and pregnancy loss in relation to indication. Br J Obstet Gynaecol 1991; 98: 892-897.
29. Daffos F, Forestier F, Capella-Pavlovsky M, et al. [Risk factors of fetal blood sampling. The essential risk is its duration]. Rev Prat 1994; 44: 923-926.
30. Duchatel F, Oury JF, Mennesson B, Muray JM. Complications of diagnostic ultrasound-guided percutaneous umbilical blood sampling: analysis of a series of cases and review of the literature. Eur J Obstet Gynecol Reprod Biol 1993; 52: 95-104.
31. Ash KM, Mibashan RS, Nicolaides KH. Diagnosis and treatment of feto-maternal hemorrhage in a fetus with homozygous von Willebrand's disease. Fetal Ther 1988; 3: 189-191.
32. Birnholz JC. Determination of fetal sex. N Engl J Med 1983; 309: 942-944.
33. Elejalde BR, de Elejalde MM, Heitman T. Visualization of the fetal genitalia by ultrasonography: a review of the literature and analysis of its accuracy and ethical implications. J Ultrasound Med 1985; 4: 633-639.
34. Whitlow BJ, Lazanakis MS, Economides DL. The sonographic identification of fetal gender from 11 to weeks of gestation. Ultrasound Obstet Gynecol 1999; 13: 301-304.
35. Mielke G, Kiesel L, Backsch C, Erz W, Gonser M. Fetal sex determination by high resolution ultrasound in early pregnancy. Eur J Ultrasound 1998; 7: 109-114.
36. Efrat Z, Akinfenwa OO, Nicolaides KH. First-trimester determination of fetal gender by ultrasound. Ultrasound Obstet Gynecol 1999; 13: 305-307.
37. Hyett JA, Gardener G, Stojilkovic-Mikic T, et al. Reduction in diagnostic and therapeutic interventions by non-invasive determination of fetal sex in early pregnancy. Prenat Diagn 2005; 25: 1111-1116.
38. Avent ND, Chitty LS. Non-invasive diagnosis of fetal sex; utilisation of free fetal DNA in maternal plasma and ultrasound. Prenat Diagn 2006; 26: 598-603.
39. Benott B. Early fetal gender determination. Ultrasound Obstet Gynecol 1999; 13: 299-300.
40. Mazza V, Contu G, Falcinelli C, et al. Biometrical threshold of biparietal diameter for certain fetal sex assignment by ultrasound. Ultrasound Obstet Gynecol 1999; 13: 308-311.
41. Mazza V, Di Monte, I, Pati M, et al. Sonographic biometrical range of external genitalia differentiation in the first trimester of pregnancy: analysis of 2593 cases. Prenat Diagn 2004; 24: 677-684.
42. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485-487.
43. Elias S, Price J, Dockter M, et al. First trimester prenatal diagnosis of trisomy 21 in fetal cells from maternal blood. Lancet 1992; 340: 1033.
44. de la Cruz F, Shifrin H, Elias S, et al. Prenatal diagnosis by use of fetal cells isolated from maternal blood. Am J Obstet Gynecol 1995; 173: 1354-1355.
45. Hahn S, Sant R, Holzgreve W. Fetal cells in maternal blood: current and future perspectives. Mol Hum Reprod 1998; 4: 515-521.
46. Hamada H, Arinami T, Kubo T, et al. Fetal nucleated cells in maternal peripheral blood: frequency and relationship to gestational age. Hum Genet 1993; 91: 427-432.
47. Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62: 768-775.
48. Invernizzi P, Biondi ML, Battezzati PM, et al. Presence of fetal DNA in maternal plasma decades after pregnancy. Hum Genet 2002; 110: 587-591.
49. Santacroce R, Vecchione G, Tomaiyolo M, et al. Identification of fetal gender in maternal blood is a helpful tool in the prenatal diagnosis of haemophilia. Hemophilia 2006; 12: 417-422.
50. Lau TW, Leung TN, Chan LY, et al. Fetal DNA clearance from maternal plasma is impaired in preeclampsia. Clin Chem 2002; 48: 2141-2146.
51. Rijnders RJ, Christiaens GC, Soussan AA, van der Schoot CE. Cell-free fetal DNA is not present in plasma of nonpregnant mothers. Clin Chem 2004; 50: 679-681.
52. Smid M, Galbiati S, Vassallo A, et al. No evidence of fetal DNA persistence in maternal plasma after pregnancy. Hum Genet 2003; 112: 617-618.
53. Johnson-Hopson CN, Artlett CM. Evidence against the long-term persistence of fetal DNA in maternal plasma after pregnancy. Hum Genet 2002; 111: 575.
54. Benachi A, Steffann J, Gautier E, et al. Fetal DNA in maternal serum: does it persist after pregnancy?. Hum Genet 2003; 113: 76-79.
55. Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999; 64: 218-224.
56. Bianchi DW, Zickwolf GK, Weil GJ, et al. Male fetal progenitor cells persist in maternal blood for as long as years postpartum. Proc Natl Acad Sci USA 1996; 93: 705-708.
57. Costa JM, Benachi A, Gautier E, et al. First-trimester fetal sex determination in maternal serum using realtime PCR. Prenat Diagn 2001; 21: 1070-1074.
58. Sekizawa A, Kondo T, Iwasaki M, et al. Accuracy of fetal gender determination by analysis of DNA in maternal plasma. Clin Chem 2001; 47: 1856-1858.
59. Honda H, Miharu N, Ohashi Y, et al. Fetal gender determination in early pregnancy through qualitative and quantitative analysis of fetal DNA in maternal serum. Hum Genet 2002; 110: 75-79.
60. Hromadnikova I, Houbova B, Hridelova D, et al. Replicate real-time PCR testing of DNA in maternal plasma increases the sensitivity of non-invasive fetal sex determination. Prenat Diagn 2003; 23: 235-238.
61. Rijnders RJ, Van Der Luijt RB, Peters ED, et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat Diagn 2003; 23: 1042-1044.
62. Rijnders RJ, Christiaens GC, Bossers B, et al. Clinical applications of cell-free fetal DNA from maternal plasma. Obstet Gynecol 2004; 103: 157-164.
63. Rijnders RJ, van der Schoot CE, Bossers B, et al. Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. Obstet Gynecol 2001; 98: 374-378.
64. Zhong XY, Holzgreve W, Hahn S. Risk free simultaneous prenatal identification of fetal Rhesus D status and sex by multiplex real-time PCR using cell free fetal DNA in maternal plasma. Swiss Med Wkly 2001; 131: 70-74.
65. Guibert J, Benachi A, Grebille AG, et al. Kinetics of SRY gene appearance in maternal serum: detection by real time PCR in early pregnancy after assisted reproductive technique. Hum Reprod 2003; 18: 1733-1736.
66. Cremonesi L, Galbiati S, Foglieni B, et al. Feasibility study for a microchip-based approach for noninvasive prenatal diagnosis of genetic diseases. Ann NY Acad Sci 2004; 1022: 105-112.
67. Birch L, English CA, O'Donoghue K, et al. Accurate and robust quantification of circulating fetal and total DNA in maternal plasma from 5 to 41 weeks of gestation. Clin Chem 2005; 51: 312-320.
68. Illanes S, Denbow M, Kailasam C, et al. Early detection of cell-free fetal DNA in maternal plasma. Early Hum Dev 2007; 83: 563-566.
69. Rodeck CH, Campbell S. Sampling pure fetal blood by fetoscopy in second trimester of pregnancy. BMJ 1978; 2: 728-730.
70. Peake IR, Bloom AL, Giddings JC, Ludlam CA. An immunoradiometric assay for procoagulant factor VIII antigen: results in haemophilia, von Willebrand's disease and fetal plasma and serum. Br J Hematol 1979; 42: 269-281.
71. Holmberg L, Gustavii B, Cordesius E, et al. Prenatal diagnosis of hemophilia B by an immunoradiometric assay of factor IX. Blood 1980; 56: 397-401.
72. Firshein SI, Hoyer LW, Lazarchick J, et al. Prenatal diagnosis of classic hemophilia. N Engl J Med 1979; 300: 937-941.
73. Mibashan RS, Rodeck CH, Thumpston JK, et al. Plasma assay of fetal factors VIIIC and IX for prenatal diagnosis of haemophilia. Lancet 1979; 1: 1309-1311.
74. Daffos F, Capella-Pavlovsky M, Forestier F. A new procedure for fetal blood sampling in utero: preliminary results of fifty-three cases. Am J Obstet Gynecol 1983; 146: 985-987.
75. Bang J, Bock JE, Trolle D. Ultrasound-guided fetal intravenous transfusion for severe rhesus haemolytic disease. BMJ (Clin Res Ed) 1982; 284: 373-374.
76. The status of fetoscopy and fetal tissue sampling. The results of the first meeting of the International Fetoscopy Group. Prenat Diagn 1984; 4: 79-81.
77. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-330.
78. Yoshitake S, Schach BG, Foster DC, et al. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985; 24: 3736-3750.
79. Ward RH, Modell B, Petrou M, et al. Method of sampling chorionic villi in first trimester of pregnancy under guidance of real time ultrasound. BMJ (Clin Res Ed) 1983; 286: 1542-1544.
80. Smidt-Jensen S, Hahnemann N. Transabdominal fine needle biopsy from chorionic villi in the first trimester. Prenat Diagn 1984; 4: 163-169.
81. Gitschier J, Lawn RM, Rotblat F, et al. Antenatal diagnosis and carrier detection of haemophilia A using factor VIII gene probe. Lancet 1985; 1: 1093-1094.
82. Chan V, Tong TM, Chan TP, et al. Multiple XbaI polymorphisms for carrier detection and prenatal diagnosis of haemophilia A. Br J Hematol 1989; 73: 497-500.
83. Pecorara M, Casarino L, Mori PG, et al. Hemophilia A: carrier detection and prenatal diagnosis by DNA analysis. Blood 1987; 70: 531-535.
84. Sampietro M, Camerino G, Romano M, et al. Combined use of DNA probes in first-trimester prenatal diagnosis of hemophilia A. Thromb Haemost 1987; 58: 988-992.
85. Brocker-Vriends AH, Briet E, Kanhai HH, et al. First trimester prenatal diagnosis of haemophilia A: two years' experience. Prenat Diagn 1988; 8: 411-421.
86. Chistolini A, Papacchini M, Mazzucconi MG, et al. Carrier detection and prenatal diagnosis in haemophilia A and B. Hematologica 1990; 75: 424-428.
87. Sacchi E, Randi AM, Tagliavacca L, et al. Carrier detection and prenatal diagnosis of hemophilia A: 5-years experience at a hemophilia center. Int J Clin Lab Res 1992; 21: 310-313.
88. Lavergne JM, Laurian Y, Dudilleux A, et al. Carrier detection and prenatal diagnosis in 98 families of haemophilia A by linkage analysis and direct detection of mutations. Blood Coagul Fibrinolysis 1991; 2: 293-301.
89. Van de Water NS, Ockelford PA, Berry EW, Browett PJ. Haemophilia management: the application of DNA analysis for prenatal diagnosis. N Z Med J 1991; 104: 443-446.
90. Caprino D, Acquila M, Mori PG. Carrier detection and prenatal diagnosis of hemophilia B with more advanced techniques. Ann Hematol 1993; 67: 289-293.
91. Acquila M, Bottini F, Valetto A, et al. A new strategy for prenatal diagnosis in a sporadic haemophilia B family. Hemophilia 2001; 7: 416-418.
92. Ludwig M, Brackmann HH, Olek K. Prenatal diagnosis of haemophilia B by the use of polymerase chain reaction and direct sequencing. Klin Wochenschr 1991; 69: 196-200.
93. Ljung R, Green P, Sjorin E, et al. Antenatal diagnosis of haemophilia B by amplification and electrophoresis of an exon fragment with a short deletion. Eur J Hematol 1992; 49: 215-218.
94. Schwartz M, Cooper DN, Millar DS, et al. Prenatal exclusion of haemophilia A and carrier testing by direct detection of a disease lesion. Prenat Diagn 1992; 12: 861-866.
95. Salviato R, Belvini D, Zanotto D, et al. Prenatal diagnosis of haemophilia A by using intron 1 inversion detection. Hemophilia 2007; 13: 772-774.
96. Chowdhury MR, Tiwari M, Kabra M, Menon PS. Prenatal diagnosis in hemophilia A using factor VIII gene polymorphism -Indian experience. Ann Hematol 2003; 82: 427-430.
97. Shetty S, Ghosh K, Bhide A, Mohanty D. Carrier detection and prenatal diagnosis in families with haemophilia. Natl Med J India 2001; 14: 81-83.
98. Panigrahi I, Ahmed RP, Kannan M, et al. Cord blood analysis for prenatal diagnosis of thalassemia major and hemophilia A. Indian Pediatr 2005; 42: 577-581.
99. Shetty S, Ghosh K, Mohanty D. Prenatal diagnosis in a haemophilia A family by both factor VIII activity and antigen measurements. J Assoc Physicians India 2003; 51: 916-918.
100. Shetty S, Ghosh K. Robustness of factor assays following cordocentesis in the prenatal diagnosis of haemophilia and other bleeding disorders. Hemophilia 2007; 13: 172-177.
101. Chi C, Hyett JA, Finning KM, et al. Non-invasive first trimester determination of fetal gender: a new approach for prenatal diagnosis of haemophilia. Br J Obstet Gynaecol 2006; 113: 239-242.
102. Costa JM, Benachi A, Gautier E. New strategy for prenatal diagnosis of X-linked disorders. N Engl J Med 2002; 346: 1502.
103. Mazza V, Falcinelli C, Percesepe A, et al. Non-invasive first trimester fetal gender assignment in pregnancies at risk for X-linked recessive diseases. Prenat Diagn 2002; 22: 919-924.
104. Trasi S, Mohanty D, Shetty S, Ghosh K. Prenatal diagnosis of von Willebrand disease in a family. Natl Med J India 2005; 18: 187-188.
105. Hoyer LW, Lindsten J, Blomback M, et al. Prenatal evaluation of fetus at risk for severe von Willebrand's disease. Lancet 1979; 2: 191-192.
106. Rodeck CH, Mibashan RS, Peake IR, Bloom AL. Prenatal diagnosis of severe von Willebrand's disease. Lancet 1979; 2: 637-638.
107. Rothschild C, Forestier F, Daffos F, et al. Prenatal diagnosis in type IIA von Willebrand disease. Nouv Rev Fr Hematol 1990; 32: 125-127.
108. Peake IR, Bowen D, Bignell P, et al. Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene. Blood 1990; 76: 555-561.
109. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders -review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
110. Peyvandi F, Jayandharan G, Chandy M, et al. Genetic diagnosis of haemophilia and other inherited bleeding disorders. Hemophilia 2006; 12 (Suppl 3): 82-89.
111. Millar DS, Cooper DN, Kakkar VV, et al. Prenatal exclusion of severe factor VII deficiency by DNA sequencing. Lancet 1992; 339: 1359.
112. McVey JH, Boswell EJ, Takamiya O, et al. Exclusion of the first EGF domain of factor VII by a splice site mutation causes lethal factor VII deficiency. Blood 1998; 92: 920-926.
113. Giansily-Blaizot M, Aguilar-Martinez P, Mazurier C, et al. Prenatal diagnosis of severe factor VII deficiency using mutation detection and linkage analysis. Br J Haematol 2001; 112: 251-252.
114. Ariffin H, Millar DS, Cooper DN, et al. Prenatal exclusion of severe factor VII deficiency. J Pediatr Hematol Oncol 2003; 25: 418-420.
115. Camire R, Ann DR, Day GA, III, et al. Prenatal diagnosis of factor X deficiency using a combination of direct mutation detection and linkage analysis with an intragenic single nucleotide polymorphism. Prenat Diagn 2003; 23: 457-460.
116. Ingerslev J, Herlin T, Sorensen B, et al. Severe factor X deficiency in a pair of siblings: clinical presentation, phenotypic and genotypic features, prenatal diagnosis and treatment. Haemophilia 2007; 13: 334-336.
117. Kangsadalampai S, Coggan M, Caglayan SH, et al. Application of HUMF13A01 (AAAG)n STR polymorphism to the genetic diagnosis of coagulation factor XIII deficiency. Thromb Haemost 1996; 76: 879-882.
118. Killick CJ, Barton CJ, Aslam S, Standen G. Prenatal diagnosis in factor XIII-A deficiency. Arch Dis Child Fetal Neonatal Ed 1999; 80: F238-F239.
119. Mota L, Ghosh K, Shetty S. Second trimester antenatal diagnosis in rare coagulation factor deficiencies. J Pediatr Hematol Oncol 2007; 29: 137-139.
120. Handyside AH, Pattinson JK, Penketh RJ, et al. Biopsy of human preimplantation embryos and sexing by DNA amplification. Lancet 1989; 1: 347-349.
121. Handyside AH, Kontogianni EH, Hardy K, Winston RM. Pregnancies from biopsied human preimplantation embryos sexed by Y-specific DNA amplification. Nature 1990; 344: 768-770.
122. Braude P, Pickering S, Flinter F, Ogilvie CM. Preimplanta-tion genetic diagnosis. Nat Rev Genet 2002; 3: 941953.
123. Sermon KD, Michiels A, Harton G, et al. ESHRE PGD Consortium data collection VI: cycles from January to December 2003 with pregnancy follow-up to October 2004. Hum Reprod 2007; 22: 323-336.
124. Verlinsky Y, Rechitsky S, Cieslak J, et al. Preimplantation diagnosis of single gene disorders by two-step oocyte genetic analysis using first and second polar body. Biochem Mol Med 1997; 62: 182-187.
125. Strom CM, Ginsberg N, Rechitsky S, et al. Three births after preimplantation genetic diagnosis for cystic fibrosis with sequential first and second polar body analysis. Am J Obstet Gynecol 1998; 178: 1298-1306.
126. Tomi D, Griesinger G, Schultze-Mosgau A, et al. Polar body diagnosis for hemophilia A using multiplex PCR for linked polymorphic markers. J Histochem Cytochem 2005; 53: 277-280.
127. Hardy K, Martin KL, Leese HJ, et al. Human preimplantation development in vitro is not adversely affected by biopsy at the 8-cell stage. Hum Reprod 1990; 5: 708-714.
128. Van de Velde H, De Vos A, Sermon K, et al. Embryo implantation after biopsy of one or two cells from cleavage-stage embryos with a view to preimplantation genetic diagnosis. Prenat Diagn 2000; 20: 1030-1037.
129. Jones GM, Trounson AO, Lolatgis N, Wood C. Factors affecting the success of human blastocyst development and pregnancy following in vitro fertilization and embryo transfer. Fertil Steril 1998; 70: 1022-1029.
130. Schoolcraft WB, Gardner DK, Lane M, et al. Blastocyst culture and transfer: analysis of results and parameters affecting outcome in two in vitro fertilization programs. Fertil Steril 1999; 72: 604-609.
131. Sermon K, Van Steirteghem A, Liebaers I. Preimplantation genetic diagnosis. Lancet 2004; 363: 1633-1641.
132. Fiorentino F, Magli MC, Podini D, et al. The minisequencing method: an alternative strategy for preimplantation genetic diagnosis of single gene disorders. Mol Hum Reprod 2003; 9: 399-410.
133. Michaelides K, Tuddenham EG, Turner C, et al. Live birth following the first mutation specific preimplantation genetic diagnosis for haemophilia A. Thromb Hemost 2006; 95: 373-379.
134. Gigarel N, Frydman N, Burlet P, et al. Single cell coamplification of polymorphic markers for the indirect preimplantation genetic diagnosis of hemophilia A, Xlinked adrenoleukodystrophy, X-linked hydrocephalus and incontinentia pigmenti loci on Xq28. Hum Genet 2004; 114: 298-305.
135. Department of Health. Preimplantation genetic diagnosis (PGD): guiding principles for commissioners of NHS services. Department of Health: London 2002.
136. Thornhill AR, deDie-Smulders CE, Geraedts JP, et al. ESHRE PGD Consortium "Best practice guidelines for clinical preimplantation genetic diagnosis (PGD and preimplantation genetic screening (PGS)". Hum Reprod 2005; 20: 35-48.
137. Levinson G, Keyvanfar K, Wu JC, et al. DNA-based Xenriched sperm separation as an adjunct to preimplantation genetic testing for the prevention of X-linked disease. Hum Reprod 1995; 10: 979-982.
138. Fugger EF, Black SH, Keyvanfar K, Schulman JD. Births of normal daughters after MicroSort sperm separation and intrauterine insemination, in-vitro fertilization, or intracytoplasmic sperm injection. Hum Reprod 1998; 13: 2367-2370.
139. Sumner AT, Robinson JA. A difference in dry mass between the heads of X- and Y-bearing human spermatozoa. J Reprod Fertil 1976; 48: 9-15.
140. Cui KH. Size differences between human X and Y spermatozoa and prefertilization diagnosis. Mol Hum Reprod 1997; 3: 61-67.
141. Johnson LA, Welch GR, Keyvanfar K, et al. Gender preselection in humans?. Flow cytometric separation of X and Y spermatozoa for the prevention of X-linked diseases. Hum Reprod 1993; 8: 1733-1739.
142. Claassens OE, Oosthuizen CJ, Brusnicky J, et al. Fluorescent in situ hybridization evaluation of human Y-bearing spermatozoa separated by albumin density gradients. Fertil Steril 1995; 63: 417-418.
143. Wang HX, Flaherty SP, Swann NJ, Matthews CD. Assessment of the separation of X- and Y-bearing sperm on albumin gradients using double-label fluorescence in situ hybridization. Fertil Steril 1994; 61: 720-726.
144. Flaherty SP, Michalowska J, Swann NJ, et al. Albumin gradients do not enrich Y-bearing human spermatozoa. Hum Reprod 1997; 12: 938-942.
145. HFEA. Sex selection: options for regulation. HFEA: London, 2003.
146. Lobel SM, Pomponio RJ, Mutter GL. The sex ratio of normal and manipulated human sperm quantitated by the polymerase chain reaction. Fertil Steril 1993; 59: 387-392.
147. Vidal F, Moragas M, Catala V, et al. Sephadex filtration and human serum albumin gradients do not select spermatozoa by sex chromosome: a fluorescent in-situ hybridization study. Hum Reprod 1993; 8: 1740-1743.
148. Wang HX, Flaherty SP, Swann NJ, Matthews CD. Discontinuous Percoll gradients enrich X-bearing human spermatozoa: a study using double-label fluorescence in-situ hybridization. Hum Reprod 1994; 9: 1265-1270.
149. Lin SP, Lee RK, Tsai YJ, et al. Separating X-bearing human spermatozoa through a discontinuous Percoll density gradient proved to be inefficient by double-label fluorescent in situ hybridization. J Assist Reprod Genet 1998; 15: 565-569.
150. Vidal F, Fugger EF, Blanco J, et al. Efficiency of Micro- Sort flow cytometry for producing sperm populations enriched in X- or Y-chromosome haplotypes: a blind trial assessed by double and triple colour fluorescent insitu hybridization. Hum Reprod 1998; 13: 308-312.
151. Fugger EF. Clinical experience with flow cytometric separation of human X- and Y-chromosome bearing sperm. Theriogenology 1999; 52: 1435-1440.
152. Bjorndahl L, Barratt CLR. Sex selection: a survey of laboratory methods and clinical results. HFEA scientific paper: London, 2002.
153. HFEA. HFEA sex selection consultation. HFEA: London, 1993.
154. HFEA. Sex selection: choice and responsibility in human reproduction. HFEA consultation: London, 2002.
155. Saito H, Sekizawa A, Morimoto T, et al. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet 2000; 356: 1170.
156. Li Y, Holzgreve W, Page-Christiaens GC, et al. Improved prenatal detection of a fetal point mutation for achondroplasia by the use of size-fractionated circulatory DNA in maternal plasma -case report. Prenat Diagn 2004; 24: 896-898.
157. Amicucci P, Gennarelli M, Novelli G, Dallapiccola B. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin Chem 2000; 46: 301-302.
158. Li Y, Di Naro E, Vitucci A, et al. Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma. JAMA 2005; 293: 843-849.
159. Chiu RW, Lau TK, Leung TN, et al. Prenatal exclusion of beta thalassaemia major by examination of maternal plasma. Lancet 2002; 360: 998-1000.
160. Vrettou C, Traeger-Synodinos J, Tzetis M, et al. Rapid screening of multiple beta-globin gene mutations by real-time PCR on the LightCycler: application to carrier screening and prenatal diagnosis of thalassemia syndromes. Clin Chem 2003; 49: 769-776.
161. Nasis O, Thompson S, Hong T, et al. Improvement in sensitivity of allele-specific PCR facilitates reliable noninvasive prenatal detection of cystic fibrosis. Clin Chem 2004; 50: 694-701.
162. Gonzalez-Gonzalez MC, Garcia-Hoyos M, Trujillo MJ, et al. Prenatal detection of a cystic fibrosis mutation in fetal DNA from maternal plasma. Prenat Diagn 2002; 22: 946-948.
163. Lo YM. Recent developments in fetal nucleic acids in maternal plasma: implications to noninvasive prenatal fetal blood group genotyping. Transfus Clin Biol 2006; 13: 50-52.
164. Schroder J, Tiilikainen A, De la Chapelle A. Fetal leukocytes in the maternal circulation after delivery. I. Cytological aspects. Transplantation 1974; 17: 346-354.
165. Hsieh TT, Pao CC, Hor JJ, Kao SM. Presence of fetal cells in maternal circulation after delivery. Hum Genet 1993; 92: 204-205.
166. Liou JD, Hsieh TT, Pao CC. Presence of cells of fetal origin in maternal circulation of pregnant women. Ann NY Acad Sci 1994; 731: 237-241.
167. Bertero MT, Camaschella C, Serra A, et al. Circulating "trophoblast" cells in pregnancy have maternal genetic markers. Prenat Diagn 1988; 8: 585-590.
168. Covone AE, Kozma R, Johnson PM, et al. Analysis of peripheral maternal blood samples for the presence of placenta-derived cells using Y-specific probes and McAb H315. Prenat Diagn 1988; 8: 591-607.
169. Ganshirt D, Garritsen H, Miny P, Holzgreve W. Fetal cells in maternal circulation throughout gestation. Lancet 1994; 343: 1038-1039.
170. Pearson HA. Life-span of the fetal red blood cell. J Pediatr 1967; 70: 166-171.
171. Bianchi DW, Flint AF, Pizzimenti MF, et al. Isolation of fetal DNA from nucleated erythrocytes in maternal blood. Proc Natl Acad Sci USA 1990; 87: 3279-3283.
172. Holzgreve W, Garritsen HS, Ganshirt-Ahlert D. Fetal cells in the maternal circulation. J Reprod Med 1992; 37: 410-418.
173. Hamada H, Arinami T, Sohda S, et al. Mid-trimester fetal sex determination from maternal peripheral blood by fluorescence in situ hybridization without enrichment of fetal cells. Prenat Diagn 1995; 15: 78-81.
174. Slunga-Tallberg A, el Rifai W, Keinanen M, et al. Maternal origin of nucleated erythrocytes in peripheral venous blood of pregnant women. Hum Genet 1995; 96: 53-57.
175. Slunga-Tallberg A, el Rifai W, Keinanen M, et al. Maternal origin of transferrin receptor positive cells in venous blood of pregnant women. Clin Genet 1996; 49: 196-199.
176. Kadir RA, Sabin CA, Goldman E, et al. Reproductive choices of women in families with haemophilia. Hemophilia 2000; 6: 33-40.
177. Beeson D, Golbus MS. Decision making: whether or not to have prenatal diagnosis and abortion for Xlinked conditions. Am J Med Genet 1985; 20: 107-114.
178. Kadir RA, Sabin CA, Goldman E, et al. Reproductive choices of women in families with haemophilia. Hemophilia 2000; 6: 33-40.
179. Kraus EM, Brettler DB. Assessment of reproductive risks and intentions by mothers of children with hemophilia. Am J Med Genet 1988; 31: 259-267.
180. Tedgard U, Ljung R, McNeil TF. Reproductive choices of haemophilia carriers. Br J Hematol 1999; 106: 421-426.
181. Varekamp I, Suurmeijer TP, Brocker-Vriends AH, et al. Carrier testing and prenatal diagnosis for hemophilia: experiences and attitudes of 549 potential and obligate carriers. Am J Med Genet 1990; 37: 147-154.
182. Markova I, Forbes CD, Inwood M. The consumers' views of genetic counseling of hemophilia. Am J Med Genet 1984; 17: 741-752.
183. Francis RB, Jr., Kasper CK. Reproduction in hemophilia. JAMA 1983; 250: 3192-3195.
184. Kadir RA, Economides DL, Braithwaite J, et al. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol 1997; 104: 803-810.
185. Chi C, Lee CA, Shiltagh N, et al. Pregnancy in carriers of haemophilia. Hemophilia 2008; 14: 56-64.
186. Hoyer LW, Carta CA, Golbus MS, et al. Prenatal diagnosis of classic hemophilia (hemophilia A by immunoradiometric assays. Blood 1985; 65: 1312-1317.
187. Tedgard U, Ljung R, McNeil TF. How do carriers of hemophilia and their spouses experience prenatal diagnosis by chorionic villus sampling?. Clin Genet 1999; 55: 26-33.
188. Karimi M, Peyvandi F, Siboni S, et al. Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy. Hemophilia 2004; 10: 367-369.
189. Pandey GS, Panigrahi I, Phadke SR, Mittal B. Knowledge and attitudes towards haemophilia: the family side and role of haemophilia societies. Community Genet 2003; 6: 120-122.
190. Peyvandi F. Carrier detection and prenatal diagnosis of hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 544-554.
191. Ghosh K, Shetty S, Pawar A, Mohanty D. Carrier detection and prenatal diagnosis in haemophilia in India: realities and challenges. Hemophilia 2002; 8: 51-55.
192. Sjogren B, Uddenberg N. Prenatal diagnosis for psychological reasons: comparison with other indications, advanced maternal age and known genetic risk. Prenat Diagn 1990; 10: 111-120.
193. Evers-Kiebooms G, Swerts A, van den Berge H. Psychological aspects of amniocentesis: anxiety feelings in three different risk groups. Clin Genet 1988; 33: 196-206.
194. Robinson J, Tennes K, Robinson A. Amniocentesis: its impact on mothers and infants. A 1-year follow-up study. Clin Genet 1975; 8: 97-106.
195. Spencer JW, Cox DN. Emotional responses of pregnant women to chorionic villi sampling or amniocentesis. Am J Obstet Gynecol 1987; 157: 1155-1160.
196. Robinson GE, Garner DM, Olmsted MP, et al. Anxiety reduction after chorionic villus sampling and genetic amniocentesis. Am J Obstet Gynecol 1988; 159: 953-956.
197. Sjogren B, Uddenberg N. Prenatal diagnosis and psychological distress: amniocentesis or chorionic villus biopsy?. Prenat Diagn 1989; 9: 477-487.
198. Black RB. A 1 and 6 month follow-up of prenatal diagnosis patients who lost pregnancies. Prenat Diagn 1989; 9: 795-804.
199. Tedgard, Ljung R, McNeil T, et al. How do carriers of hemophilia experience prenatal diagnosis (PND)?. Carriers' immediate and later reactions to amniocentesis and fetal blood sampling. Acta Paediatr Scand 1989; 78: 692-700.
200. Tedgard U, Ljung R, McNeil TF, Tedgard E. Identifying carriers at high risk for negative reactions when performing prenatal diagnosis of haemophilia. Hemophilia 1997; 3: 123-130.
201. Derogatis LR, Lipman RS, Cleary PA. Confirmation of the dimensional structure of the SCL-90. A study in construct validity. J Clin Psychol 1977; 33: 981-989.
202. Tedgard U, Ljung R, McNeil TF. Long-term psychological effects of carrier testing and prenatal diagnosis of haemophilia: comparison with a control group. Prenat Diagn 1999; 19: 411-417.
203. Larsson SA, Nilsson IM, Blomback M. Current status of Swedish haemophiliacs. I. A demographic survey. Acta Med Scand 1982; 212: 195-200.
204. Ljung R, Kling S, Tedgard U. The impact of prenatal diagnosis on the incidence of haemophilia in Sweden. Hemophilia 1995; 1: 190-193.
205. Kadir RA, Sabin CA, Goldman E, et al. Reproductive choices of women in families with haemophilia. Hemophilia 2000; 6: 33-40.